Table 2

 Six month outcomes in patients stratified by CYP3A4 metabolised statin use

OutcomeAll patients with acute coronary syndromes
No clopidogrel + no statin (n = 331)Clopidogrel + no statin (n = 180)Clopidogrel + CYP3A4 (n = 561)Clopidogrel + non-CYP3A4 (n = 91)p Value*
*Comparisons between patients who received CYP3A4 statin versus a non-CYP3A4 statin with clopidogrel.
MACE, major adverse cardiac outcomes (composite of death, MI, and stroke).
Death57 (17.2%)18 (10%)32 (5.7%)3 (3.3%)0.24
MI14 (8.3%)10 (8.9%)28 (7.6%)9 (9.7%)0.39
Stroke3 (1.1%)2 (1.3%)5 (1.4%)0 (0%)0.70
MACE73 (22.1%)30 (16.7%)64 (11.4%)12 (13.2%)0.54